Download MendeleyPhosphorylation-dependent pseudokinase domain dimerization drives full-length MLKL oligomerization.
Meng, Y., Garnish, S.E., Davies, K.A., Black, K.A., Leis, A.P., Horne, C.R., Hildebrand, J.M., Hoblos, H., Fitzgibbon, C., Young, S.N., Dite, T., Dagley, L.F., Venkat, A., Kannan, N., Koide, A., Koide, S., Glukhova, A., Czabotar, P.E., Murphy, J.M.(2023) Nat Commun 14: 6804-6804
- PubMed: 37884510
- DOI: https://doi.org/10.1038/s41467-023-42255-w
- Primary Citation of Related Structures:
8SLZ - PubMed Abstract:
The necroptosis pathway is a lytic, pro-inflammatory mode of cell death that is widely implicated in human disease, including renal, pulmonary, gut and skin inflammatory pathologies. The precise mechanism of the terminal steps in the pathway, where the RIPK3 kinase phosphorylates and triggers a conformation change and oligomerization of the terminal pathway effector, MLKL, are only emerging. Here, we structurally identify RIPK3-mediated phosphorylation of the human MLKL activation loop as a cue for MLKL pseudokinase domain dimerization. MLKL pseudokinase domain dimerization subsequently drives formation of elongated homotetramers. Negative stain electron microscopy and modelling support nucleation of the MLKL tetramer assembly by a central coiled coil formed by the extended, ~80 Å brace helix that connects the pseudokinase and executioner four-helix bundle domains. Mutational data assert MLKL tetramerization as an essential prerequisite step to enable the release and reorganization of four-helix bundle domains for membrane permeabilization and cell death.
Organizational Affiliation:
Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC, 3052, Australia.
